首页> 外文期刊>Urology >Hydronephrosis is an independent predictor of poor clinical outcome in patients treated for muscle-invasive transitional cell carcinoma with radical cystectomy.
【24h】

Hydronephrosis is an independent predictor of poor clinical outcome in patients treated for muscle-invasive transitional cell carcinoma with radical cystectomy.

机译:肾积水是根治性膀胱切除术治疗肌肉浸润性移行细胞癌患者临床预后不良的独立预测因素。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: The purpose of this study was to assess the prognostic significance of hydronephrosis on pathologic and clinical outcomes in muscle-invasive bladder cancer. METHODS: We performed a retrospective evaluation of a prospectively maintained cystectomy database and identified patients with hydronephrosis on preoperative imaging. Of a total of 306 patients, 57 (19%) had unilateral hydronephrosis and 17 (6%) had bilateral hydronephrosis. We constructed multivariate Cox regression analysis and Kaplan Meier tables to evaluate the association between preoperative hydronephrosis and clinical outcomes. RESULTS: In patients without hydronephrosis, 41.4% had extravesical disease compared with 56.1% and 64.7% in patients with unilateral or bilateral hydronephrosis, respectively. Mean overall survival (OS) among patients without hydronephrosis, with unilateral hydronephrosis, and with bilateral hydronephrosis was 55.5, 42.1, and 22.2 months, respectively. Five-year OS and disease-specific survival (DSS) was46%, 35%, and 22% (P = .001) and 68%, 54%, and 35% (P = .002), respectively. Multivariate analysis demonstrated that both unilateral and bilateral hydronephrosis are significant independent risk factors for DSS and OS. Bilateral hydronephrosis was found to have a hazard ratio of 3.87 (95% confidence interval [CI] = 1.71-8.78, P = .001) and 2.75 (95% CI = 1.45-5.18, P = .002) for DSS and OS, respectively. The hazard ratios for unilateral hydronephrosis were 1.7 (95% CI = 1.05-2.87, P = .03) and 1.5 (95% CI = 1.03-2.23, P = .04) for DSS and OS, respectively. CONCLUSIONS: Preoperative hydronephrosis is associated with a significantly poorer prognosis in patients with muscle-invasive bladder cancer. These patients should be appropriately counseled with regard to overall prognosis and the potential benefit of neoadjuvant chemotherapy.
机译:目的:本研究的目的是评估肾积水对肌肉浸润性膀胱癌的病理和临床预后的预后意义。方法:我们对前瞻性维护的膀胱切除术数据库进行了回顾性评估,并在术前影像学检查中发现了肾积水患者。在306名患者中,有57名(19%)患有单侧肾积水,而17名(6%)则患有双侧肾积水。我们构建了多元Cox回归分析和Kaplan Meier表,以评估术前肾积水与临床结局之间的关联。结果:在没有肾积水的患者中,膀胱外疾病为41.4%,而单侧或双侧肾积水的患者分别为56.1%和64.7%。没有肾积水,单侧肾积水和双侧肾积水的患者的平均总生存期(OS)分别为55.5、42.1和22.2个月。五年OS和疾病特异性生存率(DSS)分别为46%,35%和22%(P = .001)和68%,54%和35%(P = .002)。多因素分析表明,单侧和双侧肾积水都是DSS和OS的重要独立危险因素。对于DSS和OS,发现双侧肾积水的危险比为3.87(95%置信区间[CI] = 1.71-8.78,P = .001)和2.75(95%CI = 1.45-5.18,P = .002),分别。 DSS和OS的单侧肾积水的危险比分别为1.7(95%CI = 1.05-2.87,P = .03)和1.5(95%CI = 1.03-2.23,P = .04)。结论:术前肾积水与肌肉浸润性膀胱癌患者的预后明显差有关。应就总体预后和新辅助化疗的潜在益处对这些患者进行适当的咨询。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号